Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic...